Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors.

Mithramycin (MTM), a cytotoxic compound, is currently being investigated for its anti-angiogenic activity that seems to be mediated through an inhibition of the transcription factor SP1. In this study we evaluated its anti-myeloma effects in the syngenic 5TGM1 model in vitro as well as in vivo. In v...

Full description

Bibliographic Details
Main Authors: Eléonore Otjacques, Marilène Binsfeld, Natacha Rocks, Silvia Blacher, Karin Vanderkerken, Agnès Noel, Yves Beguin, Didier Cataldo, Jo Caers
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3646989?pdf=render